Michael Polsky, MD
Sleep Medicine · North Chesterfield, VANPI 1992816706
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (51.4%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. Inspire Medical Systems, Inc. accounts for 90.0% of it on its own, with 38 other manufacturers making up the rest. 2025 is the largest year on record at $77,858, more than ten times the $773 reported in 2019. Among sleep medicine clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 583 payments — averaging $169.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Inspire Medical Systems, Inc.$89K
- Jazz Pharmaceuticals Inc.$3K
- AstraZeneca$1K
- GSK$981
- Harmony Biosciences LLC$831
- Philips North America LLC$404
- plus $3K from 33 others
Across 24 payments — averaging $341.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Inspire Medical Systems, Inc.$8K
What the payments were for
- Consulting fees$50,70051%
- Speaking & faculty fees$18,00018%
- Travel & lodging$13,08213%
- Food & beverage$16,56017%
- Education$3730%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Inspire Medical Systems, Inc. | 199 | $88,832 |
| Jazz Pharmaceuticals Inc. | 49 | $3,212 |
| AstraZeneca | 47 | $1,127 |
| GSK | 70 | $981 |
| Harmony Biosciences LLC | 31 | $831 |
| Philips North America LLC | 20 | $404 |
| Boehringer Ingelheim | 18 | $349 |
| Axsome Therapeutics, Inc. | 15 | $307 |
| Amgen | 12 | $266 |
| Avadel CNS Pharmaceuticals, LLC | 10 | $264 |
| Sanofi | 12 | $230 |
| Baxter Healthcare | 8 | $213 |
| Inogen, Inc. | 8 | $161 |
| Genentech USA, Inc. | 11 | $155 |
| Grifols USA, LLC | 7 | $146 |
| Novartis | 7 | $121 |
| Mylan Specialty L.p. | 8 | $116 |
| Regeneron Healthcare Solutions, Inc. | 6 | $105 |
| Mallinckrodt Hospital Products Inc. | 4 | $98 |
| Lilly USA, LLC | 5 | $89 |
| ANI Pharmaceuticals, Inc. | 2 | $65 |
| United Therapeutics Corporation | 3 | $59 |
| Ensodata, Inc. | 1 | $53 |
| Verona Pharma, Inc. | 3 | $50 |
| Electromed, Inc. | 4 | $50 |
| Insmed, Inc. | 3 | $46 |
| Resmed Corp | 3 | $46 |
| Intuitive Surgical | 1 | $44 |
| Vanda Pharmaceuticals Inc. | 2 | $38 |
| Atricure, Inc. | 1 | $34 |
| Arbor Pharmaceuticals, Inc. | 2 | $32 |
| Pharming Healthcare, Inc. | 2 | $30 |
| Biogen | 1 | $27 |
| Circassia Inc. | 2 | $24 |
| Bayer | 2 | $24 |
| Pulmonx Corporation | 1 | $23 |
| 3b Medical, Inc. | 1 | $22 |
| Paratek Pharmaceuticals, Inc. | 1 | $21 |
| Tactile Systems Technology Inc | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$98,715 in reported general payments places this provider in the 95th percentile of 74 sleep medicine providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ZemairaAlpha-1-Proteinase Inhibitor | 12 | $119,205 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $10,315 |
| Modafinil | 16 | $725 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 15 | $398 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 11 | $361 |
| Montelukast Sodium | 11 | $141 |
| Gabapentin | 13 | $39 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta | $981 | $10,31512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 74 sleep medicine providers in Virginia.
Other sleep medicine in North Chesterfield
- Barry KatchinoffNorth Chesterfield$510
- William WinterCharlottesville$1.1M
- Astaad DalalFalls Church$99K
- Douglas PuryearMidlothian$49K
- Marc RaphaelsonLeesburg$47K
- Shahriar ShahzeidiLeesburg$27K
- Pascal NgongmonWoodbridge$25K
- Amit PatelFalls Church$14K
- Richard ParisiWilliamsburg$8K
- Vandana DhawanChesapeake$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.